Fred Hutchinson Cancer Center
Seattle, Washington, United States
Purpose
To support a phase 2a trial to assess the safety and immunogenicity of the MTBVAC TB vaccine candidate in People Living with HIV.
Division
Global Health
Date
October 2025
Region Served
AFRICA, AMERICA
Committed amount
$1,999,264
Grant topic
Tuberculosis
Duration (months)
27
Grantee location
Seattle, Washington, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.